×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KURA – kura oncology, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KURA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/5
07:21 am
kura
Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
12/4
08:12 am
kura
Kura Oncology: A Cautious Buy [Seeking Alpha]
Low
Report
Kura Oncology: A Cautious Buy [Seeking Alpha]
12/3
07:02 pm
kura
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]
Low
Report
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia [Yahoo! Finance]
12/3
08:32 am
kura
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
Medium
Report
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
12/2
06:42 pm
kura
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data [Seeking Alpha]
Medium
Report
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data [Seeking Alpha]
12/2
08:02 am
kura
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Low
Report
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
11/25
05:16 pm
kura
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
Low
Report
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
11/25
05:21 am
kura
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed [Yahoo! Finance]
Medium
Report
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
12/5
07:21 am
Reiterates
Market Outperform
Market Outperform
Citigroup Inc.
Medium
Report
-4.0%
Date
Time
Symbol
Headline
Impact
12/2
08:10 am
kura
Form 8-K Kura Oncology, Inc. For: Dec 02
Medium
Report
Form 8-K Kura Oncology, Inc. For: Dec 02
11/14
08:00 pm
kura
Form 144 Kura Oncology, Inc. Filed by: Leoni Mollie
Medium
Report
Form 144 Kura Oncology, Inc. Filed by: Leoni Mollie
11/14
08:00 pm
kura
Form 4 Kura Oncology, Inc. For: Nov 13 Filed by: FORD KATHLEEN
Medium
Report
Form 4 Kura Oncology, Inc. For: Nov 13 Filed by: FORD KATHLEEN
11/14
08:00 pm
kura
Form 144 Kura Oncology, Inc. Filed by: FORD KATHLEEN
Medium
Report
Form 144 Kura Oncology, Inc. Filed by: FORD KATHLEEN
11/14
08:00 pm
kura
Form 144 Kura Oncology, Inc. Filed by: Powl Brian T.
Medium
Report
Form 144 Kura Oncology, Inc. Filed by: Powl Brian T.
11/14
08:00 pm
kura
Form 4 Kura Oncology, Inc. For: Nov 13 Filed by: WILSON TROY EDWARD
Medium
Report
Form 4 Kura Oncology, Inc. For: Nov 13 Filed by: WILSON TROY EDWARD
11/14
08:00 pm
kura
Form 4 Kura Oncology, Inc. For: Nov 13 Filed by: Bair Teresa Brophy
Medium
Report
Form 4 Kura Oncology, Inc. For: Nov 13 Filed by: Bair Teresa Brophy
11/14
08:00 pm
kura
Form 144 Kura Oncology, Inc. Filed by: Bair Teresa Brophy
Medium
Report
Form 144 Kura Oncology, Inc. Filed by: Bair Teresa Brophy
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock.
41.3%
5/7 Q1/2019 3/31/2019 EPS -0.370 ZacksConsensus -0.450 ActVsEst 0.080 - Beat 9.6%
5/24 Kura Oncology Inc (NASDAQ: KURA) had its price target raised by analysts at Citigroup Inc from $18.00 to $25.00. They now have a "buy" rating on the stock. 8.3%
4/9 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 7.9%
3/19 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.4%
6/18 Form 424B5 Kura Oncology, Inc. 7.1%
9/5 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. 5.9%
10/15 Kura Oncology Expands Board of Directors with Appointment of Diane Parks 4.9%
6/17 Kura Oncology Inc (NASDAQ: KURA) had its "positive" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $23.00. 4.6%
2/29 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. 4.1%
5/7 Q1/2019 3/31/2019 EPS -0.370 ZacksConsensus -0.450 ActVsEst 0.080 - Beat 9.6%
5/24 Kura Oncology Inc (NASDAQ: KURA) had its price target raised by analysts at Citigroup Inc from $18.00 to $25.00. They now have a "buy" rating on the stock. 8.3%
4/9 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 7.9%
3/19 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.4%
6/18 Form 424B5 Kura Oncology, Inc. 7.1%
9/5 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. 5.9%
10/15 Kura Oncology Expands Board of Directors with Appointment of Diane Parks 4.9%
6/17 Kura Oncology Inc (NASDAQ: KURA) had its "positive" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $23.00. 4.6%
2/29 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. 4.1%
TOP News Decliners
3/17
Kura Oncology (KURA) Presents At Cowen and Compnay Health Care Conference - Slideshow [Seeking Alpha]
-14.5%
3/11 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.8%
6/14 Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal [MarketWatch] -5.0%
8/2 Kura Oncology, Inc. 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] -4.8%
7/18 Kura Oncology Inc (NASDAQ: KURA) is now covered by analysts at Deutsche Bank AG. They set a "buy" rating and a $28.00 price target on the stock. -4.5%
8/21 Form S-3/A Kura Oncology, Inc. -4.4%
3/4 Form 8-K Kura Oncology, Inc. For: Mar 03 -4.3%
8/21 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.0%
3/17 Form CT ORDER Kura Oncology, Inc. -3.9%
1/23 Kura Oncology Announces Transition of Chief Medical Officer -3.8%
3/11 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.8%
6/14 Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal [MarketWatch] -5.0%
8/2 Kura Oncology, Inc. 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] -4.8%
7/18 Kura Oncology Inc (NASDAQ: KURA) is now covered by analysts at Deutsche Bank AG. They set a "buy" rating and a $28.00 price target on the stock. -4.5%
8/21 Form S-3/A Kura Oncology, Inc. -4.4%
3/4 Form 8-K Kura Oncology, Inc. For: Mar 03 -4.3%
8/21 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.0%
3/17 Form CT ORDER Kura Oncology, Inc. -3.9%
1/23 Kura Oncology Announces Transition of Chief Medical Officer -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: